 I. To determine the maximum tolerated dose MTD of enzalutamide when given in combination with metformin metformin hydrochloride to patients with castration resistant prostate cancer CRPC, where fewer than 33 of patients experienced dose limiting toxicity DLT attributable to the study regimen and to recommend a phase II dose for the combination. 